SURMOUNT-5 Trial Overview SURMOUNT-5 (NCT05822830) is a multicenter, randomized, open-label Phase 3b trial aimed at assessing the efficacy and safety of Zepbound (tirzepatide) compared to Wegovy (semaglutide) in adults with obesity or overweight, with at least one comorbidity (such as hypertension, dyslipidemia, obstructive sleep apnea (OSA), or cardiovascular disease), and no diabetes
In its ubiquinol state, it provides a vital line of antioxidant defense
All products are manufactured in Korea
The credible explanation for any weight loss from the gelatin trick to lose weight is much simpler: it is a pre-meal protein preload
Prescription items are NON-RETURNABLE and NON-REFUNDABLE
For more on GI side effects during treatment, our article on semaglutide side effects long term offers additional context